[18F]DRKXH1:一种用于阿尔茨海默病的新型β-淀粉样蛋白PET示踪剂的临床前与临床研究
本研究合成新型Aβ PET示踪剂[18F]DRKXH1,通过生物分布、小动物PET-CT动态扫描、离体与体外放射自显影及人体PET评估其性能。结果显示该示踪剂放化产率40%、比活度156.64±11.55 GBq/μmol,主要经肝、肾排泄,在AD转基因小鼠脑皮层与海马有较高摄取,皮层DVR高于WT小鼠(P<0.0001),且DVR高于[18F]AV45(1.29±0.05 vs. 1.05±0.08;P=0.0003)。人体初步研究显示AD患者皮层高滞留而健康对照均匀低摄取,提示其有潜力用于人脑Aβ检测。
要点
- [18F]DRKXH1自动化合成产率40%,比活度156.64±11.55 GBq/μmol。
- AD转基因小鼠皮层DVR高于WT小鼠(P<0.0001),且DVR高于[18F]AV45(P=0.0003)。
- 初步人体PET显示AD患者皮层高滞留、健康对照低摄取。
核心结论
- [18F]DRKXH1是一种在临床前研究中高灵敏度的Aβ示踪剂,具有在体内检测人脑Aβ的潜力。
研究设计与样本
- 研究包括[18F]DRKXH1的自动化合成、log D与生物分布分析、AD转基因小鼠(APPswe/PSEN1dE9)与年龄匹配正常小鼠的小动物PET-CT动态扫描、离体与体外放射自显影、免疫组化,以及2例健康对照和1例AD患者的人体PET研究。
主要发现
- [18F]DRKXH1放化产率40%,比活度156.64±11.55 GBq/μmol,主要经肝和肾排泄。
- 小动物PET显示[18F]DRKXH1初始脑摄取高、清除快,在AD转基因小鼠脑皮层和海马可检测到浓度。
- AD转基因小鼠皮层DVR高于WT小鼠(P<0.0001),基于0-60分钟动态扫描的SUVR也高于WT小鼠。
- 体外放射自显影显示示踪剂在AD转基因小鼠脑Aβ斑块富集区显著浓聚。
- [18F]DRKXH1的DVR高于[18F]AV45(1.29±0.05 vs. 1.05±0.08;t=5.33,P=0.0003)。
临床怎么用
- 基于临床前与初步人体数据,[18F]DRKXH1有潜力作为Aβ PET示踪剂用于AD的体内检测,但需进一步临床验证。
局限性
- 人体PET研究仅纳入2例健康对照和1例AD患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The deposition of β-amyloid (Aβ) in the brain is a biomarker of Alzheimer's disease (AD). Highly sensitive Aβ positron emission tomography (PET) imaging plays an essential role in diagnosing and evaluating the therapeutic effects of AD. AIM: To synthesize a new Aβ tracer [18F]DRKXH1 (5-(4-(6-(2-[18]fluoroethoxy)ethoxy)imidazo[1,2-alpha]pyridin-2-yl)phenyl) and evaluate the tracer performance by biodistribution analysis, in vivo small-animal PET-CT dynamic scan, ex vivo and in vitro autoradiography, and PET in human subjects. METHODS: [18F]DRKXH1 was synthesized automatically by the GE FN module. Log D (pH 7.4) and biodistribution of [18F]DRKXH1 were investigated. Small-animal-PET was used for [18F]DRKXH1 and [18F]AV45 imaging study in AD transgenic mice (APPswe/PSEN1dE9) and age-matched normal mice. The distribution volume ratios (DVR) and standardized uptake value ratios (SUVRs) were calculated with the cerebellum as the reference region. The deposition of Aβ plaques in the brain of AD transgenic mice was determined by ex vivo autoradiography and immunohistochemistry. In vitro autoradiography was performed in the postmortem brain sections of AD patients and healthy controls. Two healthy control subjects and one AD patient was subjected to in vivo PET study using [18F]DRKXH1. RESULTS: The yield of [18F]DRKXH1 was 40%, and the specific activity was 156.64 ± 11.55 GBq/μmol. [18F]DRKXH1 was mainly excreted through the liver and kidney. The small-animal PET study showed high initial brain uptake and rapid washout of [18F]DRKXH1. The concentration of [18F]DRKXH1 was detected in the cortex and hippocampus of AD transgenic mice brain. The cortex DVR of AD transgenic mice was higher than that of WT mice (P < 0.0001). Moreover, the SUVRs of AD transgenic mice were higher than those of WT mice based on the 0-60-min dynamic scanning. In vitro autoradiography showed a significant concentration of tracer in the Aβ plaque-rich areas in the brain of AD transgenic mice. The DVR value of [18F]-DRKXH1 is higher than that of [18F]-AV45 (1.29 ± 0.05 vs. 1.05 ± 0.08; t = 5.33, P = 0.0003). Autoradiography of postmortem human brain sections showed [18F]DRKXH1-labeled Aβ plaques in the AD brain. The AD patients had high retention in cortical regions, while healthy control subjects had uniformly low radioactivity uptake. CONCLUSIONS: [18F]DRKXH1 is an Aβ tracer with high sensitivity in preclinical study and has the potential for in vivo detection of the human brain.
引用
- Xu M, Guo J, Gu J, et al. Preclinical and clinical study on [18F]DRKXH1: a novel β-amyloid PET tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2021. PMID: 34292345. doi:10.1007/s00259-021-05421-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。